Stability-enhanced Hot-melt Extruded Amorphous Solid Dispersions via Combinations of Soluplus® and HPMCAS-HF

AAPS PharmSciTech

Volumn 16, Issue 4, 2015, Pages 824-834

  Alshahrani, Saad M ^a   Lu, Wenli ^a   Park, Jun Bom ^a   Morott, Joseph T ^a   Alsulays, Bader B ^a   Majumdar, Soumyajit ^a   Langley, Nigel ^b   Kolter, Karl ^c   Gryczke, Andreas ^c   Repka, Michael A ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b BASF CORPORATION   (United States)

^c BASF SE   (Germany)

Author keywords

carbamazepine; hot melt extrusion; HPMCAS HF; Soluplus ; stability

Indexed keywords

CARBAMAZEPINE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; POLYMER; SOLUPLUS; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; METHYLCELLULOSE; POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMER; POLYVINYL DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DELAYED DRUG RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; SOLID; THERMOSTABILITY; X RAY DIFFRACTION; ANALOGS AND DERIVATIVES; CHEMISTRY; HEAT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLUBILITY; THERMOGRAVIMETRY;

CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HOT TEMPERATURE; METHYLCELLULOSE; POLYETHYLENE GLYCOLS; POLYVINYLS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMOGRAVIMETRY; X-RAY DIFFRACTION;

EID: 84937814808     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0269-6     Document Type: Article

References (26)

1. Repka MA et al. Pharmaceutical applications of hot-melt extrusion: part II. Drug Dev Ind Pharm. 2007;33(10):1043–57.
2. Crowley MM et al. Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm. 2007;33(9):909–26.
3. Repka MA et al. Applications of hot-melt extrusion for drug delivery. 2008.
4. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water-soluble drugs. Drug Discov Today. 2007;12(23):1068–75.
5. Sotthivirat S et al. Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364. Int J Pharm. 2013;452(1):73–81.
6. Williams RO, Watts AB, Miller DA. Formulating poorly water-soluble drugs 2012: Springer.
7. Liu X et al. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm Res. 2012;29(3):806–17.
8. Li B et al. Stability and solubility enhancement of ellagic acid in cellulose ester solid dispersions. Carbohydr Polym. 2013;92(2):1443–50.
9. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide. Clin Pharmacokinet. 1986;11(3):177–98.
10. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the Biopharmaceutics Classification System. Eur J Pharm Biopharm. 2004;58(2):265–78.
11. Moneghini M et al. Study of the solid state of carbamazepine after processing with gas anti-solvent technique. Eur J Pharm Biopharm. 2003;56(2):281–9.
12. Hickey MB et al. Performance comparison of a co-crystal of carbamazepine with marketed product. Eur J Pharm Biopharm. 2007;67(1):112–9.
13. Grzesiak AL et al. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci. 2003;92(11):2260–71.
14. Hardung H, Djuric D, Ali S. Combining HME & solubilization: Soluplus®—the solid solution. Drug Deliv Technol. 2010;10(3):20–7.
15. Liu H et al. Effects of extrusion process parameters on the dissolution behavior of indomethacin in Eudragit® E PO solid dispersions. Int J Pharm. 2010;383(1):161–9.
16. Prodduturi S et al. Stabilization of hot-melt extrusion formulations containing solid solutions using polymer blends. AAPS PharmSciTech. 2007;8(2):E152–61.
17. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1–12.
18. Li B et al. Both solubility and chemical stability of curcumin are enhanced by solid dispersion in cellulose derivative matrices. Carbohydr Polym. 2013;98(1):1108–16.
19. Al-Obaidi H, Buckton G. Evaluation of griseofulvin binary and ternary solid dispersions with HPMCAS. AAPS PharmSciTech. 2009;10(4):1172–7.
20. FDA U. Guidance for industry waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) 2000.
21. Sethia S, Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm. 2004;272(1):1–10.
22. Krahn FU, Mielck JB. Effect of type and extent of crystalline order on chemical and physical stability of carbamazepine. Int J Pharm. 1989;53(1):25–34.
23. Djuris J et al. Preparation of carbamazepine–Soluplus® solid dispersions by hot-melt extrusion, and prediction of drug–polymer miscibility by thermodynamic model fitting. Eur J Pharm Biopharm. 2013;84(1):228–37.
24. Tanno F et al. Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions. Drug Dev Ind Pharm. 2004;30(1):9–17.
25. Rumondor AC, Stanford LA, Taylor LS. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res. 2009;26(12):2599–606.
26. Ueda K et al. Inhibitory effect of hydroxypropyl methylcellulose acetate succinate on drug recrystallization from a supersaturated solution assessed using nuclear magnetic resonance measurements. Mol Pharm. 2013;10(10):3801–11.